Clinical Trials Sponsored by NeuroDx Development

Total 9488 results

Janssen Research & Development, LLC

Completed

A Study for Schizophrenia Relapse Prediction

Schizophrenia

India
Janssen Research & Development, LLC

Terminated

A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis

Healthy | Colitis, Ulcerative

Germany
SPD Development Company Limited

Completed

Period Tracker Lay User Study

Menstrual Cycles

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study of Itraconazole in the Management of Superficial Fungal Infections in India

Mycoses

India
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-56136379 in Healthy Participants

Healthy
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1 (PLATFORM)

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

Healthy

Belgium
Sunovion Respiratory Development Inc.

Completed

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease (COPD)

United States
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Influenza A

United States, France, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Israel, India, Thailand, New Zealand, Vietnam, Germany, Latvia, Spain, Russian Federation, Turkey, Argentina, Singapore, Brazil, Hungary, Malaysia, Au... and more
Janssen Research & Development, LLC

Completed

A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus Infections

Japan
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Janssen Research & Development, LLC

Withdrawn

Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes

Type 2 Diabetes

Switzerland
Janssen Research & Development, LLC

Completed

Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
Janssen Research & Development, LLC

Completed

Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies

Hematologic Malignancies

United States
Janssen Research & Development, LLC

Completed

A First in Man Study of MABp1 in Patients With Advanced Cancers

Advanced Cancers

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

Lymphoma

Taiwan, China, Singapore, Korea, Republic of, Hong Kong
Janssen Research & Development, LLC

Completed

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

France, Germany
Janssen Research & Development, LLC

Completed

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Multiple Myeloma

China
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Janssen Research & Development, LLC

Completed

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Neoplasms | Colorectal Cancer | Advanced Solid Tumors | Non-small Cell Lung Cancer

France, United States
Janssen Research & Development, LLC

Withdrawn

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

Psoriatic Arthritis

United States, Germany, Spain, Poland, Romania, Canada, Russian Federation
Janssen Research & Development, LLC

Completed

A Registry of Participants With Prostate Cancer in Asia

Prostatic Neoplasms

China, Taiwan, India, Malaysia, Japan, Korea, Republic of, Singapore, Thailand
Janssen Research & Development, LLC

Completed

A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants

Healthy

Belgium
SCRI Development Innovations, LLC

Completed

Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

Metastatic Breast Cancer

United States
Janssen Research & Development, LLC

Completed

A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
Janssen Research & Development, LLC

Completed

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Uterine Hemorrhage

United States
Janssen Research & Development, LLC

Completed

A Study of Ketamine in Patients With Treatment-resistant Depression

Major Depressive Disorder

United States
Janssen Research & Development, LLC

Completed

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (SUSTAIN-1)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, Belgium, Germany, Spain, Mexico, Turkey, Canada, Brazil, Estonia, Hungary, Slovakia, Sweden, Czechia
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Hepatitis C

Singapore, Canada, Poland, New Zealand
Janssen Research & Development, LLC

Completed

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Healthy

United States
Janssen Research & Development, LLC

Completed

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Poland, Germany, Spain, Mexico, Australia, Taiwan, Argentina, Hungary
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants

Healthy

Belgium, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants

Healthy

Belgium
Gage Development Company, LLC

Completed

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

Actinic Keratosis

United States
Janssen Research & Development, LLC

Terminated

Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

Respiratory Syncytial Viruses

Australia, France, United Kingdom, Belgium, Taiwan, United States, Spain, Argentina, Mexico, Bulgaria, Malaysia, Japan, Sweden, Korea, Republic of, Canada, Netherlands, Brazil, Germany, Poland
Janssen Research & Development, LLC

Terminated

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

Healthy

Belgium
Janssen Research & Development, LLC

Completed

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin (COMETA)

Diabetes Mellitus, Type 2

Mexico
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Ukraine, Taiwan, Poland, Korea, Republic of, Russian Federation, Czechia
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Canada, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Portugal, Bulgaria, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia

3

Subscribe